PIS
MACK

POM Investment Strategies’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

POM Investment Strategies’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-69
Closed -$1.02K – 332
2024
Q1 		$1.02K Buy
+69
New +$969 ﹤0.01% 222

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

POM Investment Strategies's MACK Position: Q2 2024 in Review

POM Investment Strategies sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 69 shares — an estimated $1.02K sold.

POM Investment Strategies first reported a position in MACK in Q1 2024 and held it in 1 quarter. The position peaked at $1.02K in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • POM Investment Strategies reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • POM Investment Strategies sold 69 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.02K.
  • POM Investment Strategies first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
  • POM Investment Strategies's Merrimack Pharmaceuticals, Inc. position peaked at $1.02K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on POM Investment Strategies's 13F filing for Q2 2024, filed 25 Jul 2024.